

Adult dosing¹

One-time initial loading dose¹:

4 x 150-mg prefilled syringes (600 mg)

Maintenance dose¹:

2 x 150-mg prefilled syringes
every other week (300 mg)

Your patients. Your choice.
Dosing flexibility after 16 weeks^{*}

CONTINUE
every other week
2 x 150-mg
prefilled syringes
(300 mg)¹

OR

REDUCE*
to once-monthly
2 x 150-mg
prefilled syringes
(300 mg)^{1*}

*May be considered in adult patients <100 kg (220 lbs) who achieve clear or almost clear skin after 16 weeks of treatment.



Beth, a real Adbry patient.
Individual results may vary.



Pediatric dosing (12-17 years)¹

One-time initial loading dose¹:

2 x 150-mg prefilled syringes (300 mg)

Maintenance dose¹:

1 x 150-mg prefilled syringe
every other week


Not an actual patient.
Individual results may vary.


IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

- ADBRY is contraindicated in patients who have known hypersensitivity to tralokinumab-ldrm or any excipients in ADBRY.

Please see Important Safety Information on reverse side and accompanying full Prescribing Information.


Adbry[®]
(tralokinumab-ldrm)
Injection 150 mg/mL



Scan for info on
savings and support
[AdbryHCP.com](https://www.adbryhcp.com)

INDICATION

ADBRY® (tralokinumab-ldrm) injection is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

- ADBRY is contraindicated in patients who have known hypersensitivity to tralokinumab-ldrm or any excipients in ADBRY.

WARNINGS AND PRECAUTIONS

- **Hypersensitivity:** Hypersensitivity reactions, including anaphylaxis and angioedema have occurred after administration of ADBRY. If a serious hypersensitivity reaction occurs, discontinue ADBRY immediately and initiate appropriate therapy.
- **Conjunctivitis and Keratitis:** Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received ADBRY. Conjunctivitis was the most frequently reported eye disorder. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.
- **Parasitic (Helminth) Infections:** Treat patients with pre-existing helminth infections before initiating treatment with ADBRY. If patients become infected while receiving ADBRY and do not respond to antihelminth treatment, discontinue treatment with ADBRY until the infection resolves.
- **Risk of Infection with Live Vaccines:** ADBRY may alter a patient's immunity and increase the risk of infection following administration of live vaccines. Prior to initiating therapy with ADBRY, complete all age appropriate vaccinations according to current immunization guidelines. Avoid use of live vaccines during treatment with ADBRY. Limited data are available regarding coadministration of ADBRY with non-live vaccines.

ADVERSE REACTIONS

- The most common adverse reactions (incidence $\geq 1\%$) are upper respiratory infections, conjunctivitis, injection site reactions, and eosinophilia.

USE IN SPECIFIC POPULATIONS


- **Pregnancy:** There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADBRY during pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-877-311-8972 or visiting <https://mothertobaby.org/ongoing-study/adbry-tralokinumab/>. There are limited data from the use of ADBRY in pregnant women to inform a drug-associated risk of adverse developmental outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, ADBRY may be transmitted from the mother to the developing fetus.
- **Lactation:** There are no data on the presence of tralokinumab-ldrm in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is present in breast milk. The effects of local gastrointestinal exposure and limited systemic exposure to ADBRY on the breastfed infant are unknown.
- **Pediatric Use:** Safety and effectiveness of ADBRY have not been established in pediatric patients younger than 12 years of age.

Please see accompanying full Prescribing Information.

Reference: 1. ADBRY. Prescribing information. LEO Pharma Inc; December 2023.



The LEO Pharma logo and Adbry® are registered trademarks of LEO Pharma A/S. © 2024 LEO Pharma Inc. All rights reserved. MAT-73006 May 2024



Adbry[®]
(tralokinumab-ldrm)
Injection 150 mg/mL